Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Cibus, Inc. (CLXT)
|
Add to portfolio |
|
|
|
| Price: |
$5.90
| | Metrics |
| OS: |
21.3
|
M
| |
|
|
| Market cap: |
$126
|
M
| |
|
|
|
Net cash:
|
$48.6
|
M
| |
$2.28
|
per share
|
|
EV:
|
$77
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.2 | 26.0 | 23.9 | 7.3 | 0.2 | 0.5 | 0.4 | 1.3 |
| Revenue growth | -99.4% | 9.0% | 226.9% | 2991.5% | -53.5% | 27.3% | -68.6% | |
| Cost of goods sold | 0.0 | 28.6 | 35.1 | 9.3 | 0.0 | 0.0 | 0.2 | 0.8 |
| Gross profit | 0.2 | -2.6 | -11.3 | -2.0 | 0.2 | 0.5 | 0.2 | 0.5 |
| Gross margin | 100.0% | -9.9% | -47.3% | -27.2% | 100.0% | 100.0% | 49.9% | 41.0% |
| Selling, general and administrative | | | | | | 14.7 | 6.7 | 3.6 |
| Sales and marketing | 11.0 | 15.4 | 20.8 | 24.1 | 2.4 | | | |
| Research and development | 11.6 | 11.3 | 11.1 | | 10.4 | 11.6 | 5.6 | 2.8 |
| General and administrative | | | | | 13.4 | | | |
| EBIT | -22.4 | -29.3 | -43.8 | -38.1 | -28.1 | -25.8 | -12.1 | -5.8 |
| EBIT margin | -14248.4% | -112.9% | -183.8% | -522.1% | -11913.1% | -5076.6% | -3034.8% | -457.1% |
| Pre-tax income | -16.9 | -29.2 | -44.8 | -39.6 | -27.9 | -26.0 | -12.1 | -5.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -16.9 | -29.2 | -44.8 | -39.6 | -27.9 | -26.0 | -12.1 | -5.9 |
| Net margin | -10764.3% | -112.4% | -188.0% | -542.9% | -11820.8% | -5114.2% | -3029.1% | -463.0% |
| |
| Diluted EPS | ($0.37) | ($0.78) | ($1.32) | ($1.21) | ($0.91) | ($1.12) | ($0.62) | ($0.88) |
| Shares outstanding (diluted) | 46.0 | 37.5 | 33.9 | 32.8 | 30.7 | 23.2 | 19.6 | 6.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|